Lendlease to build large-scale Singapore vaccine facility in late-2021

Vivienne Tay

Published Thu, Oct 7, 2021 · 10:16 AM

SYDNEY-BASED Lendlease, which manages Singapore-listed Lendlease Global Commercial Reit, is commencing construction on a large-scale, greenfield vaccine facility in late-2021. It did not disclose the identity of the client.

The move comes as the Republic sees an increase in the number of Covid-19 vaccine-related investments, with three major pharmaceutical companies - BioNTech, Sanofi and Thermo Fisher Scientific - having plans to set up vaccine manufacturing facilities here.

The new facility will leverage the real estate group's digital capabilities, best practices in construction and experience in the sector, it said in a press statement on Thursday. It added that it has built more than 90 per cent of the biotechnology facilities in JTC's Tuas Biomedical Park since the late-1990s.

Lendlease has also been appointed to take on additional projects for existing Singapore clients, including expanding existing facilities to enhance their capabilities.

Lendlease Asia chief executive Justin Gabbani said the life sciences sector is one of the group's key focus areas where it is looking to apply its expertise across the integrated real estate value chain.

In March 2021, Lendlease inked a partnership in the US with institutional investor Ivanhoe Cambridge to develop the 60 Guest Street project in Boston, a 320,000 square foot life sciences hub.